Literature DB >> 10191208

The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease.

H Ghiasi1, S Cai, S M Slanina, G C Perng, A B Nesburn, S L Wechsler.   

Abstract

To assess the relative effect of interleukin (IL)-2- and IL-4-dependent immune responses on herpes simplex virus (HSV)-1 infection, naive, vaccinated, and mock-vaccinated IL-20/0 and IL-40/0 knockout mice were challenged ocularly with HSV-1. Naive IL-20/0 mice were significantly more susceptible to lethal infection than IL-40/0 or parental BALB/c mice. Vaccinated, IL-20/0, IL-40/0, and BALB/c mice induced similar neutralizing antibody titers and were completely protected against HSV-1-induced death and corneal scarring. Vaccinated and mock-vaccinated IL-20/0 mice had significantly higher HSV-1 titers in their eyes than BALB/c mice, while vaccinated and mock-vaccinated IL-40/0 mice had significantly lower HSV-1 titers in their eyes than BALB/c mice. Recombinant (r) IL-2 treatment of the IL-20/0 mice significantly reduced ocular HSV-1 replications, but rIL-4 treatment of IL-40/0 mice significantly increased ocular HSV-1 replications. Th1 (IL-2) cytokine responses may help protect mice against ocular HSV-1 challenge and reduce ocular HSV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191208     DOI: 10.1086/314736

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  The Absence of DHHC3 Affects Primary and Latent Herpes Simplex Virus 1 Infection.

Authors:  Shaohui Wang; Kevin R Mott; Marianne Cilluffo; Casey L Kilpatrick; Shoko Murakami; Alexander V Ljubimov; Konstantin G Kousoulas; Sita Awasthi; Bernhard Luscher; Homayon Ghiasi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

2.  Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines.

Authors:  A Heiligenhaus; H Li; A Schmitz; S Wasmuth; D Bauer
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

3.  Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice.

Authors:  H Ghiasi; Y Osorio; G C Perng; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  The expression of IL-2 and IL-4 in CD4(+) T cells from mouse lymph nodes and spleen during HSV-1-induced facial palsy.

Authors:  Lintao Gu; Yuechen Han; Wenwen Liu; Yanyan Mao; Jianfeng Li; Haibo Wang
Journal:  Inflamm Res       Date:  2013-11-27       Impact factor: 4.575

6.  Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.

Authors:  Harry Matundan; Kevin R Mott; Homayon Ghiasi
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

7.  An increase in herpes simplex virus type 1 in the anterior segment of the eye is linked to a deficiency in NK cell infiltration in mice deficient in CXCR3.

Authors:  Daniel J J Carr; Todd Wuest; John Ash
Journal:  J Interferon Cytokine Res       Date:  2008-04       Impact factor: 2.607

8.  Role of interleukin-2 and herpes simplex virus 1 in central nervous system demyelination in mice.

Authors:  Kevin R Mott; Mandana Zandian; Sariah J Allen; Homayon Ghiasi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 9.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

10.  Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Mol Vis       Date:  2010-01-26       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.